ETON ▲ +1.6% - Eton Pharmaceuticals, Inc. $ETON Eton Pharmaceuticals: Launches ET-900 Program for Pediatric Epileptic Spasms, Targets Phase 2 Trial in Q1 2027 ? • Licensing: Secures Baylor College of Medicine patent rights for IGF-1 treatment of infantile and epileptic spasms, retaining commercial rights. • Preclinical Data: IGF-1 reduced daily spasms by ~50% and eliminated them in 20% of treated animals. • Phase 2: IND submitted for a study enrolling up to 20 children, with initial dosing planned for Q1 2027. • Pipeline: ET-900 uses mecasermin, the active ingredient in Eton's existing INCRELEX product, expanding into pediatric neurology. 02-NOV-2026 06:57 AM ET